Sakuma M, Haferlach T, Walter W
Oncotarget. 2024; 15:644-658.
PMID: 39347709
PMC: 11441413.
DOI: 10.18632/oncotarget.28646.
Adachi S, Kirino Y, Higashitani K, Hirahara L, Maeda A, Horita N
Rheumatol Adv Pract. 2024; 8(2):rkae065.
PMID: 38854419
PMC: 11157137.
DOI: 10.1093/rap/rkae065.
Ma Y, Hu S, Ni R, Liu W, Fu A, Sha M
Pract Lab Med. 2024; 39:e00380.
PMID: 38715663
PMC: 11075056.
DOI: 10.1016/j.plabm.2024.e00380.
Nicholson L, Cowen E, Beck D, Ferrada M, Madigan L
JID Innov. 2023; 4(1):100242.
PMID: 38130326
PMC: 10733701.
DOI: 10.1016/j.xjidi.2023.100242.
Gutierrez-Rodrigues F, Wells K, Jones A, Hironaka D, Rankin C, Gadina M
Ann Rheum Dis. 2023; 83(4):508-517.
PMID: 38049983
PMC: 10939924.
DOI: 10.1136/ard-2023-224933.
Clonal haematopoiesis and UBA1 mutations in individuals with biopsy-proven giant cell arteritis and population-based controls.
Salzbrunn J, van Zeventer I, de Graaf A, Kamphuis P, van Bergen M, van Sleen Y
Rheumatology (Oxford). 2023; 63(2):e45-e47.
PMID: 37632778
PMC: 10836998.
DOI: 10.1093/rheumatology/kead435.
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.
Sakuma M, Blombery P, Meggendorfer M, Haferlach C, Lindauer M, Martens U
Leukemia. 2023; 37(5):1080-1091.
PMID: 36823397
PMC: 10169658.
DOI: 10.1038/s41375-023-01857-5.
[Macrocytic anemia and polychondritis: VEXAS syndrome].
Zeisbrich M, Schindler V, Krausz M, Proietti M, Mrovecova P, Voll R
Z Rheumatol. 2023; 83(3):229-233.
PMID: 36735069
PMC: 10973061.
DOI: 10.1007/s00393-023-01318-5.
Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck D, Bodian D, Shah V, Mirshahi U, Kim J, Ding Y
JAMA. 2023; 329(4):318-324.
PMID: 36692560
PMC: 10408261.
DOI: 10.1001/jama.2022.24836.
VEXAS syndrome: a new paradigm for adult-onset monogenic autoinflammatory diseases.
Vitale A, Caggiano V, Bimonte A, Caroni F, Tosi G, Fabbiani A
Intern Emerg Med. 2023; 18(3):711-722.
PMID: 36662445
PMC: 10082120.
DOI: 10.1007/s11739-023-03193-z.
Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review.
Kouranloo K, Ashley A, Zhao S, Dey M
Rheumatol Int. 2023; 43(6):1023-1032.
PMID: 36617363
PMC: 10126013.
DOI: 10.1007/s00296-022-05266-2.
Autoinflammatory manifestations in adult patients.
Rodolfi S, Nasone I, Folci M, Selmi C, Brunetta E
Clin Exp Immunol. 2022; 210(3):295-308.
PMID: 36334040
PMC: 9985169.
DOI: 10.1093/cei/uxac098.
Vasculitis associated with VEXAS syndrome: A literature review.
Watanabe R, Kiji M, Hashimoto M
Front Med (Lausanne). 2022; 9:983939.
PMID: 36045928
PMC: 9420898.
DOI: 10.3389/fmed.2022.983939.
Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis.
Ferrada M, Savic S, Ospina Cardona D, Collins J, Alessi H, Gutierrez-Rodrigues F
Blood. 2022; 140(13):1496-1506.
PMID: 35793467
PMC: 9523373.
DOI: 10.1182/blood.2022016985.
